Published in Neuropsychologia on May 01, 1996
Visuoperceptual repetition priming and progression of parkinsonian signs in aging. Neurobiol Aging (2007) 0.78
Dissociation between Conceptual and Perceptual Implicit Memory: Evidence from Patients with Frontal and Occipital Lobe Lesions. Front Hum Neurosci (2016) 0.76
Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology (2009) 3.49
The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry (1998) 2.88
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology (2007) 2.63
Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology (2009) 2.27
Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry (2008) 2.12
Hemispheric asymmetries in activation and integration of categorical information. Laterality (2000) 2.09
Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology (2006) 1.85
Validity of clinical diagnosis in dementia: a prospective clinicopathological study. J Neurol Neurosurg Psychiatry (1985) 1.54
In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology (2009) 1.47
Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (2000) 1.41
PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord (2008) 1.39
Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry (1998) 1.39
Role of the dopaminergic system in chronic pain -- a fluorodopa-PET study. Pain (2001) 1.37
Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol (2000) 1.36
PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain (2008) 1.34
Longitudinal cognitive changes in traumatic brain injury: a 30-year follow-up study. Neurology (2006) 1.33
Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology (2011) 1.26
Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry (2004) 1.24
C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry (2004) 1.23
Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain (2001) 1.22
An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology (2000) 1.22
The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain (1997) 1.18
Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. J Nucl Med (2000) 1.14
Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord (2001) 1.13
Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. Am J Psychiatry (2001) 1.11
Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci (1997) 1.07
Variant Alzheimer's disease with spastic paraparesis: clinical characterization. Neurology (2000) 1.06
The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med J (2000) 1.06
Androgen deprivation and cognition in prostate cancer. Br J Cancer (2003) 1.04
Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett (2001) 1.03
The Glu318Gly mutation of the presenilin-1 gene does not necessarily cause Alzheimer's disease. Ann Neurol (1998) 1.03
Decreased striatal dopamine transporter density in JNCL patients with parkinsonian symptoms. Neurology (2000) 1.01
Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy. Brain (2008) 1.01
Interaction between estrogen receptor 1 and the epsilon4 allele of apolipoprotein E increases the risk of familial Alzheimer's disease in women. Neurosci Lett (2000) 1.00
Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology (2000) 1.00
Personality traits and brain dopaminergic function in Parkinson's disease. Proc Natl Acad Sci U S A (2001) 0.99
Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol (1998) 0.99
Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol (2000) 0.99
The effect of short-term estrogen replacement therapy on cognition: a randomized, double-blind, cross-over trial in postmenopausal women. Obstet Gynecol (1998) 0.98
An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp Neurol (2000) 0.98
Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord (1990) 0.98
Mapping brain structure and personality in late adulthood. Neuroimage (2004) 0.96
Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. Neurobiol Dis (2001) 0.95
Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther (2009) 0.94
Semantic processing of spoken words in Alzheimer's disease: an electrophysiological study. J Cogn Neurosci (1998) 0.94
Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cereb Blood Flow Metab (2000) 0.93
123I-IPT brain SPECT study in essential tremor and Parkinson's disease. Neurology (1999) 0.93
Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients. Eur J Neurol (2013) 0.92
Unbiased morphometrical measurements show loss of pigmented nigral neurones with ageing. Neuropathol Appl Neurobiol (1999) 0.92
[11 C]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy: correlation with hippocampal MR volumetry, T2 relaxometry, and neuropathology. Neurology (2000) 0.92
Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol (2001) 0.91
Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci (2003) 0.90
Predictive factors for cognitive deterioration and dementia in Parkinson's disease. Adv Neurol (1987) 0.90
Hippocampal volume, brain atrophy, and APOE genotype after traumatic brain injury. Neurology (2006) 0.90
Slowing of information processing in Parkinson's disease. Brain Cogn (1993) 0.90
Visual object recognition in early Alzheimer's disease: deficits in semantic processing. Acta Neurol Scand (2003) 0.90
Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. Neuroimage (2012) 0.89
Automatic and controlled information processing in multiple sclerosis. Brain (1994) 0.89
Quality of life and cognitive performance after carotid endarterectomy during long-term follow-up. Acta Neurol Scand (1992) 0.89
Phenotype of a homozygous CADASIL patient in comparison to 9 age-matched heterozygous patients with the same R133C Notch3 mutation. Stroke (2001) 0.88
Cell counts in the substantia nigra: a comparison of single section counts and disector counts in patients with Parkinson's disease and in controls. Neuropathol Appl Neurobiol (1995) 0.88
Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study. J Neural Transm (Vienna) (2003) 0.87
A quantitative morphometrical study of neuron degeneration in the substantia nigra in Parkinson's disease. J Neurol Sci (1996) 0.87
Association and causal relationship of midlife obesity and related metabolic disorders with old age cognition. Curr Alzheimer Res (2011) 0.86
Neuritic degeneration in the hippocampus and amygdala in Parkinson's disease in relation to Alzheimer pathology. Acta Neuropathol (1999) 0.86
Dystonia after head trauma. Neurology (1994) 0.86
Neuronal size and density in the nucleus basalis of Meynert in Alzheimer's disease. J Neurol Sci (1987) 0.86
PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology (2000) 0.85
Left hemisphere activation during processing of morphologically complex word forms in adults. Neurosci Lett (1999) 0.85
Autonomic dysfunction in recent onset and advanced Parkinson's disease. Clin Neurol Neurosurg (1988) 0.85
Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm Park Dis Dement Sect (1995) 0.85
Hippocampal MRI volumetry in cognitively discordant monozygotic twin pairs. J Neurol Neurosurg Psychiatry (2004) 0.85
Cognitive functioning in severe somatization--a pilot study. Acta Psychiatr Scand (2002) 0.85
[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment. Eur J Nucl Med Mol Imaging (2013) 0.83
CADASIL: hereditary disease of arteries causing brain infarcts and dementia. Neuropathol Appl Neurobiol (1999) 0.83
Automatic influences of memory in Alzheimer's disease. Cortex (1998) 0.82
APOE-epsilon4 predicts dementia but not other psychiatric disorders after traumatic brain injury. Neurology (2004) 0.82
Do carriers of POLG mutation W748S have disease manifestations? Clin Genet (2007) 0.81
Dopaminergic neurotransmission in chronic herpes simplex virus brain infection in rabbits. J Neural Transm Gen Sect (1993) 0.81
Single section and disector counts in evaluating neuronal loss from the substantia nigra in patients with Parkinson's disease. Neuropathol Appl Neurobiol (1995) 0.81
Risk for Parkinson's disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J Neurol (2000) 0.80
Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI. Eur J Nucl Med Mol Imaging (2013) 0.80
Memory deficits and early cognitive deterioration in MS. Acta Neurol Scand (1996) 0.80
Decrease in mesencephalic dopamine autoreceptors in experimental herpes simplex encephalitis. J Neural Transm Gen Sect (1992) 0.80
[18F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis. J Neurol Neurosurg Psychiatry (1997) 0.80
Apolipoprotein E epsilon4 allele frequency is increased in Parkinson's disease only with co-existing Alzheimer pathology. Acta Neuropathol (1998) 0.80
Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study. Brain (1995) 0.79
Association of an interleukin 1B gene polymorphism (-511) with Parkinson's disease in Finnish patients. J Med Genet (2002) 0.79
Neuropsychological disturbances and cerebral atrophy determined by computerized tomography in parkinsonian patients with long-term levodopa treatment. Adv Neurol (1984) 0.79
Brain dopamine D-2 receptors in senile dementia. J Neural Transm (1986) 0.78
Muscarinic and dopaminergic receptors in the aging human brain. Brain Res (1987) 0.78
Dopamine D-1 receptors in the parkinsonian brain. Brain Res (1985) 0.78
[18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology (1992) 0.78
Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease. Q J Nucl Med Mol Imaging (2011) 0.78